Abbott received CE Mark approval in Europe for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, on January 20, 2026. The device treats atrial fibrillation (AFib). The catheter advances the company's pulsed field ablation (PFA) technology portfolio. The first commercial procedures using the device are complete in the European Union.
The catheter features dual-energy capability. It allows physicians to deliver both radiofrequency (RF) energy and pulsed field ablation (PFA) energy. This design provides doctors flexibility to tailor therapy based on patient anatomy and condition. This enhances treatment for irregular heart rhythms. This approval follows the 2025 approval of Abbott's Volt PFA System.